1st May 2017

U.S. Track & Field Athlete, Molly Beckwith-Ludlow, Accepts Public Warning for ADRV

USADA announced today that Molly Beckwith-Ludlow, of Indianapolis, Ind., an athlete in the sport of track and field, has accepted a public warning for her anti-doping rule violation. Beckwith-Ludlow, 29, tested positive for hydroxyclomiphene, a metabolite of clomiphene, as a result of an out-of-competition urine sample she provided on December 21, 2016. Clomiphene is a Specified Substance in the class of Hormone and Metabolic Modulators and is prohibited at all times under the USADA Protocol for Olympic and Paralympic Movement Testing, the United States Olympic Committee National Anti-Doping Policies, and the International Association of Athletics Federations Anti-Doping Rules, all of which have adopted the World Anti-Doping Code and the World Anti-Doping Agency (WADA) Prohibited List.

After a thorough review of the case, including the examination of medical records provided by the athlete, USADA determined that Beckwith-Ludlow’s positive test was caused by clomiphene, which is medically approved by the FDA for women and which she was using in a therapeutic dose prescribed in October 2016 under the care of an obstetrician with the intention of starting a family.

• This media release was originally published by the US Anti-Doping Agency (USADA) on 1 May 2017. To access the original, please click here.

You may also like...

Pin It on Pinterest

Share This